Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on January 18, 2023. The report serves as a Regulation FD disclosure regarding an update on the company's efforts to expand access to its PainShield product. The filing incorporates a press release dated January 18, 2023, as Exhibit 99.1.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain a financial statement or quarterly results summary.
Material Changes
The material change disclosed is the issuance of a press release detailing updates on the expansion of access to the PainShield product. No financial performance changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the PainShield product access update. The filing explicitly states that the company undertakes no obligation to update, supplement, or amend the materials attached. No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this 8-K form itself.
Key Facts for Investor Verification
- Verify the specific details of the PainShield product access expansion in the attached press release (Exhibit 99.1).
- Confirm the company's current cash position and runway, as this filing does not disclose liquidity metrics.
- Review recent 10-K or 10-Q filings for the most recent audited financial data, as this 8-K contains no financial figures.
- Note that the registrant is NanoVibronix, Inc., not Envue Medical, Inc., despite the metadata request.